Novel Treatment Approaches Under Investigation for HER2+ mBC
November 23rd 2023Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.
Read More
Common Adverse Events With Second- and Third-Line Therapies in Patients With HER2+ mBC
November 16th 2023Joseph Gligorov, MD, discusses the potential side effects of second- and third-line therapies for patients with HER2+ metastatic breast cancer and highlights the low-toxicity profile of tucatinib when combined with trastuzumab and capecitabine.
Read More
French Clinical Data and Real-World Evidence on Treatment Sequencing for HER2+ mBC
November 9th 2023Dr Gligorov underscores the significance of real-world data in France supporting the effectiveness of tucatinib and trastuzumab in combination for patients with heavily pretreated HER2+ metastatic breast cancer, with notable benefits even in cases with brain metastasis.
Read More
Treatment Sequencing Approaches for Patients With HER2+ mBC
November 9th 2023Joseph Gligorov, MD, recommends using tucatinib in combination with trastuzumab and capecitabine as a preferred strategy after trastuzumab deruxtecan, favoring it over another antibody-drug conjugate (ADC) due to limited data on the latter's effectiveness.
Read More
Trastuzumab Deruxtecan for Patients With HER2+ Metastatic Breast Cancer (mBC)
November 2nd 2023Dr Joseph Gligorov highlights the impact of trastuzumab deruxtecan in treating HER2-positive breast cancer due to its impressive results in progression-free survival and overall survival, emphasizing its importance in early treatment, while acknowledging the need to monitor safety issues.
Read More